Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.5B |
| 2 |
Apple
AAPL
|
+$1.68B |
| 3 |
Tesla
TSLA
|
+$951M |
| 4 |
Johnson & Johnson
JNJ
|
+$750M |
| 5 |
UnitedHealth
UNH
|
+$703M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTXS
Citrix Systems Inc
CTXS
|
+$913M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$257M |
| 3 |
NVIDIA
NVDA
|
+$225M |
| 4 |
Vertiv
VRT
|
+$164M |
| 5 |
JPMorgan Chase
JPM
|
+$161M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.48% |
| 2 | Healthcare | 7.36% |
| 3 | Financials | 6.5% |
| 4 | Consumer Discretionary | 5.35% |
| 5 | Industrials | 3.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3426
Sprott Physical Gold and Silver Trust
CEF
$7.4B
| $351K | ﹤0.01% |
19,561
| – | – |
|
3427
Hess Midstream
HESM
$5.23B
| $350K | ﹤0.01% |
11,714
-9,479
| -45% | -$271K |
|
|
INFN
3428
DELISTED
Infinera Corporation Common Stock
INFN
| $350K | ﹤0.01% |
51,906
+33,469
| +182% | +$203K |
|
3429
QCR Holdings
QCRH
$1.71B
| $349K | ﹤0.01% |
7,029
+4,836
| +221% | +$249K |
|
3430
MasterCraft Boat Holdings
MCFT
$582M
| $348K | ﹤0.01% |
13,449
+12,693
| +1,679% | +$300K |
|
3431
CALL
Colgate-Palmolive
CL
$71.6B
| $347K | ﹤0.01% |
+4,400
| New | +$330K |
|
|
VMEO
3432
DELISTED
Vimeo
VMEO
| $346K | ﹤0.01% |
100,935
+4,764
| +5% | +$18.4K |
|
3433
Heartland Express
HTLD
$949M
| $346K | ﹤0.01% |
22,564
+10,250
| +83% | +$158K |
|
3434
iShares Biotechnology ETF
IBB
$9.18B
| $345K | ﹤0.01% |
2,628
-389,005
| -99% | -$50.3M |
|
3435
Remitly
RELY
$5.05B
| $344K | ﹤0.01% |
30,083
-53,363
| -64% | -$553K |
|
|
EFC
3436
Ellington Financial
EFC
$1.67B
| $344K | ﹤0.01% |
27,814
+12,843
| +86% | +$167K |
|
3437
Newmark Group
NMRK
$2.72B
| $344K | ﹤0.01% |
43,136
+10,065
| +30% | +$83.9K |
|
|
TRST
3438
Trustco Bank Corp NY
TRST
$975M
| $343K | ﹤0.01% |
9,134
+4,050
| +80% | +$148K |
|
|
EB
3439
DELISTED
Eventbrite
EB
| $343K | ﹤0.01% |
58,576
+31,977
| +120% | +$209K |
|
3440
iShares US Medical Devices ETF
IHI
$3.37B
| $342K | ﹤0.01% |
6,505
-990
| -13% | -$50.2K |
|
3441
Civista Bancshares
CIVB
$607M
| $342K | ﹤0.01% |
15,526
-2,642
| -15% | -$59.6K |
|
|
JMIA
3442
Jumia Technologies
JMIA
$754M
| $341K | ﹤0.01% |
106,274
| – | – |
|
3443
Tootsie Roll Industries
TR
$2.96B
| $341K | ﹤0.01% |
9,013
+3,934
| +77% | +$143K |
|
3444
Allient
ALNT
$1.53B
| $340K | ﹤0.01% |
9,776
+2,279
| +30% | +$75.1K |
|
|
CS
3445
PUT
DELISTED
Credit Suisse Group
CS
| $339K | ﹤0.01% |
+111,600
| New | +$434K |
|
3446
Gulfport Energy Corp
GPOR
$2.94B
| $339K | ﹤0.01% |
4,602
+2,696
| +141% | +$223K |
|
3447
Nicolet Bankshares
NIC
$3.64B
| $337K | ﹤0.01% |
4,228
+3,088
| +271% | +$240K |
|
3448
Protolabs
PRLB
$1.92B
| $337K | ﹤0.01% |
13,209
-7,543
| -36% | -$224K |
|
|
IAS
3449
DELISTED
Integral Ad Science
IAS
| $335K | ﹤0.01% |
38,099
+14,909
| +64% | +$126K |
|
|
CFB
3450
DELISTED
CrossFirst Bankshares, Inc. Common Stock
CFB
| $334K | ﹤0.01% |
26,941
+12,111
| +82% | +$161K |
|
Similar funds
Barclays's Q4 2022 Portfolio in Review
As of Q4 2022, Barclays held 5,646 positions worth $223B, up 144% from $91.6B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $128B of net new capital in Q4 2022, opening 798 new positions and adding to 2,634 existing holdings. Its largest new stake was Seadrill: 1,546,558 shares worth $50.5M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $257M trimmed.
- Barclays's largest Q4 2022 buy was Seadrill: 1,546,558 shares worth $50.5M.
- Barclays added most to Microsoft in Q4 2022, an estimated $2.5B increase.
- Barclays's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $257M.
- Barclays fully exited Citrix Systems Inc in Q4 2022, selling an estimated $913M.
- Barclays's ten largest holdings make up 41% of its $223B portfolio in Q4 2022.
- Barclays opened 798 new positions and closed 385 in Q4 2022.
- Barclays's portfolio value rose 144% quarter-over-quarter to $223B.
Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.